Invesco
ATOS icon

Invesco’s Atossa Therapeutics ATOS Stock Holding History

Invesco’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,911
Closed -$39.5K – 3771
2025
Q1 		$39.5K Sell
3,911
-112
-3% -$1.36K ﹤0.01% 3717
2024
Q4 		$57K Buy
4,023
+288
+8% +$5.62K ﹤0.01% 3681
2024
Q3 		$85.2K Sell
3,735
-125
-3% -$2.52K ﹤0.01% 3639
2024
Q2 		$68.9K Buy
+3,860
New +$85.4K ﹤0.01% 3791
2022
Q2 		– Sell
-2,185
Closed -$41K – 4045
2022
Q1 		$41K Sell
2,185
-47
-2% -$955 ﹤0.01% 3947
2021
Q4 		$54K Sell
2,232
-240
-10% -$8.78K ﹤0.01% 3971
2021
Q3 		$121K Sell
2,472
-120,952
-98% -$7.04M ﹤0.01% 3903
2021
Q2 		$11.7M Buy
+123,424
New +$6.53M ﹤0.01% 1956
2013
Q4 		– Sell
-19
Closed -$281K – 4328
2013
Q3 		$281K Buy
+19
New +$249K ﹤0.01% 3634

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Invesco's ATOS Position: Q2 2025 in Review

Invesco sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 3,911 shares — an estimated $39.5K sold.

Invesco first reported a position in ATOS in Q3 2013 and held it in 9 quarters. The position peaked at $11.7M in Q2 2021. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • Invesco reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 3,911 Atossa Therapeutics shares in Q2 2025, an estimated $39.5K.
  • Invesco first reported a position in Atossa Therapeutics in Q3 2013 and held it in 9 quarters.
  • Invesco's Atossa Therapeutics position peaked at $11.7M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.